EP2782569A1 — Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
Assigned to Allergan Inc · Expires 2014-10-01 · 12y expired
What this patent protects
The present invention relates to pharmaceutical compositions, containing 4-[1-(2,3-dimethylphenyl)ethyl]-1 H -imidazole, ( S ) 4-[1-(2,3-dimethylphenyl)ethyl]-1 H -imidazole or ( S ) [3-(1-(1 H -imidazol-4-yl)ethyl)-2-methylphenyl] methanol, their use as pharmaceuticals for the t…
USPTO Abstract
The present invention relates to pharmaceutical compositions, containing 4-[1-(2,3-dimethylphenyl)ethyl]-1 H -imidazole, ( S ) 4-[1-(2,3-dimethylphenyl)ethyl]-1 H -imidazole or ( S ) [3-(1-(1 H -imidazol-4-yl)ethyl)-2-methylphenyl] methanol, their use as pharmaceuticals for the treatment of retinal diseases, for retinal neuroprotection and vision enhancement.
Drugs covered by this patent
- Alphagan (BRIMONIDINE TARTRATE) · Senju Pharmaceutical Co., Ltd
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.